Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Balcinrenone Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Balcinrenone is a Small molecule drug targeting MR, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Mitiperstat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Mitiperstat is a Small molecule drug targeting MPO, at Phase 2. This 2026 report reviews clinical evidence, IP, deals, risks and a CONDITIONAL GO view.
Latest Hotspot
8 min read
Pozelimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Pozelimab is a Monoclonal antibody targeting C5, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
MBD2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for MBD2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Sunvozertinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Sunvozertinib: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Donanemab-AZBT Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Donanemab-AZBT is a Monoclonal antibody targeting pGlu3Aβ, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Talquetamab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Talquetamab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Eloralintide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Eloralintide is a Recombinant polypeptide targeting AMYR, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Cagrilintide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Cagrilintide is a Synthetic peptide targeting AMYR x CALCR, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
8 min read
MAOB 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for MAOB, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Retatrutide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Retatrutide is a Synthetic peptide targeting GCGR x GIPR x GLP-1R, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Vicadrostat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Vicadrostat is a Small molecule drug targeting CYP11B2, at Phase 3. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.